- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neuromyelitis optica spectrum disorder (NMOSD)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1339KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 208KB)
Eculizumab – November 2021
Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris®
Last updated
4 March 2022